Introduction
Prion diseases are progressive, fatal neurodegenerative illnesses. They include Creutzfeldt-Jakob disease in humans and scrapie, bovine spongiform encephalopathy, and chronic wasting disease in animals. These diseases are characterized by the accumulation of abnormal prion protein (abnormal PrP), the main component of the pathogen, and it is conformationally transformed from the normal prion protein (PrPc) (Prusiner, 1998) . Abnormal PrP forms an insoluble protein polymer with a proteaseresistant core (PrPres). The conversion of PrPc to abnormal PrP and the turnover of abnormal PrP in prion-infected cells are key events in prion disease, but they remain largely enigmatic.
As remedies for these diseases, dozens of compounds or substances reportedly either inhibit prion formation in prion-infected cultured cells or prolong incubation periods in prion-infected animals (Sim, 2012; Teruya and Doh-ura, 2013; Trevitt and Collinge, 2006) . Some are known to be effective in a prion straindependent fashion (Berry et al., 2013; Ishikawa et al., 2004 Ishikawa et al., , 2006 Kawasaki et al., 2007) , but the mechanism underlying prion straindependent efficacy remains to be determined. A few antiprion compounds have been used in clinical trials against human prion diseases, but meaningfully beneficial effects in patients have never been reported (Collinge et al., 2009; Geschwind et al., 2013; Haïk et al., 2014; Otto et al., 2004; Tsuboi et al., 2009) .
To obtain a starting point for the development of remedies and to elucidate the enigmatic PrP conversion mechanism, we have searched for compounds or substances that modify abnormal PrP formation in prion-infected cells. In earlier studies (Kocisko et al., 2003; Korth et al., 2001) , an extensive array of medicinal drugs and biological substances were screened for antiprion activity. We specifically examined untouched materials from natural products. Then we reported antiprion substances extracted from natural products such as fucoidan and proteinbound polysaccharide K (Hamanaka et al., 2011) . The insect is a yet under-cultivated natural resource that exists abundantly worldwide in terms of both number and variety. It might be possible to discover new insect-derived substances that are useful either for probing the PrP conversion mechanism or for developing therapeutic and prophylactic treatments for the illness. In fact, anticancer compounds and antivirus compounds have been found in insect extracts (Ezzati-Tabrizi et al., 2013; Natori, 1994; Ratcliffe et al., 2011; Slocinska et al., 2008) . For this study, we screened insect-derived substances, such as hormones and biological peptides, using prion-infected cells. Results showed that juvenile hormone III (JH-III) inhibited abnormal PrP formation in cells infected with the RML prion. JH-III is classified as an isoprenoid compound having a farnesane backbone. Because no reports have described the antiprion activity of isoprenoid compounds, we performed a structure-activity analysis of isoprenoid compounds and examined their antiprion mechanism in prion-infected cells. The findings indicate that the antiprion activities of isoprenoid compounds are mediated neither through the modification of PrPc and lipid rafts, nor through the prenylation of proteins. The results of this study suggest that isoprenoid compounds are a new type of probe for elucidating prion straindependent abnormal PrP formation.
Results

Antiprion activities of insect-derived substances
Using persistently prion-infected cells, we examined whether insect-derived substances have antiprion activity or not. Sixteen substances, including hormones and their analogues as well as biological peptides, were tested in three distinct prion straininfected neuroblastoma cell lines: N2a cells infected with RML prion (ScN2a cells), N2a cells infected with 22 L prion (N167 cells), and N2a cells infected with the Fukuoka-1 prion (F3 cells). Prioninfected cells were incubated with the samples at a dose of 7.5 μg/mL for three days. Then, PrPres levels were assayed by immunoblotting.
Results revealed that only JH-III reduced PrPres levels. This effect was observed in ScN2a cells, but not in N167 cells or F3 cells (Fig. 1A, lane 2) . Moreover, JH-III did not modify PrPc levels in uninfected N2a cells (Fig. 1B, lane 2) . In contrast, JH analogues such as methoprene and methoprene acid (Fig. 1A , lanes 3 and 19, respectively) were ineffective at a dose of 7.5 μg/mL, although the 50% effective concentration value (EC 50 ) of JH-III was 9.7 μM (3.0 μg/mL) (Fig. 1C) . As shown in Table 1 , JH-III has isoprene units in its chemical structure, whereas neither methoprene nor methoprene acid has an isoprene unit. Therefore, the data suggest that isoprene units are responsible for the antiprion activity of JH-III in ScN2a cells.
Antiprion activities of JH-III biosynthesis intermediates and related compounds
Actually, JH-III is an isoprenoid compound synthesized in insect cells from FOH, which comes from the isoprenoid pathway (Fig. 1D) . The isoprenoid pathway, sited downstream of the mevalonate pathway, is also present in mammals. It is enrolled in either the biosynthesis of cholesterol and steroids or the prenylation of factors such as the small G proteins. Therefore, we investigated whether other isoprenoid compounds reduce the PrPres levels in ScN2a cells (Table 1) .
The 5-carbon isoprenoid β,β-dimethyl-allylalcohol (DMAOH) was ineffective at doses for which cell damage was not observed. Similarly, 10-carbon isoprenoid compounds, including geraniol (GOH) and geranyl acetone, were ineffective at non-toxic doses. FOH was the most potent of the 15-carbon isoprenoid compounds at reducing PrPres levels. Its EC 50 was 3.0 μM. Farnesyl pyrophosphate (FPP) and farnesyl acetone were also potent: their respective EC 50 s were 6.3 μM and 6.6 μM. Farnesyl compounds in which the hydroxyl group in FOH is replaced with a halide were much less potent or impotent. The chloride showed EC 50 of 17.0 μM. The bromide was ineffective at non-toxic doses. Farnesyl acetate was also effective, with EC 50 of 9.7 μM. Among the 20-carbon isoprenoid compounds, GGOH was the most potent, with an excellent EC 50 (0.9 μM). Geranylgeranyl diphosphate (GGPP) and geranylgeranyl acetone (GGA) were also potent, with EC 50 s of 9.0 μM and 7.5 μM, respectively. An analogue of GGOH was less effective, with EC 50 of 23.2 μM. Isoprenoid compounds having carbon chains longer than 20 carbons had no potency or much less potency. The 30-carbon isoprenoid squalene was ineffective at non-toxic doses and 40-carbon β-carotene showed an EC 50 4 30 μM. These 
Effects of isoprenoid compounds on PrPc and other related factors
The two isoprenoid compounds, FOH and GGOH, were analyzed further as representatives. These compounds showed antiprion activities in a prion-strain dependent fashion similar to that of JH-III (Fig. 2A) . The compounds did not modify PrPc levels (Fig. 2B) or the cell surface PrPc levels in N2a cells (Fig. 2C) , suggesting that the compounds exert their antiprion activities without modifying PrPc turnover or metabolism.
Autophagy has been reported to regulate abnormal PrP clearance (Heiseke et al., 2010) . Therefore, we examined whether autophagosome formation is enhanced in ScN2a cells treated with the isoprenoids. Results showed that these compounds did not modify the levels of the autophagosomal membrane-specific phosphatidylethanolamine-conjugated form of LC3 (LC3-II) in the cells (Fig. 2D) , indicating the compounds neither enhanced autophagosome synthesis nor reduced autophagosome turnover.
Compounds such as tetracyclines (Tagliavini et al., 2000) and polycationic compounds (Supattapone et al., 2009 ) reportedly convert abnormal PrP molecules to less protease-resistant PrP molecules when cell lysates containing abnormal PrP molecules are incubated with these compounds. Therefore, we tested whether FOH and GGOH modify the protease sensitivity of abnormal PrP molecules. Results showed that the isoprenoid compounds did not change the protease sensitivity of isoprenoid-incubated abnormal PrP molecules and did not modify the stability of PrPc molecules (Fig. 2E) .
GGA, which is used as an antiulcer medicine in clinical settings, protects the stomach from mucosal damage by inducing HSP70 expression (Hirakawa et al., 1996) . Conversely, GGA at high concentrations reportedly induces GRP78 expression through endoplasmic reticulum stress, even in the absence of HSP70 induction (Endo et al., 2007) . Therefore, we analyzed the expression levels of HSP70 and GRP78 in ScN2a cells treated with the isoprenoid compounds. Results showed that the levels of HSP70 and GRP78 were not modified by these compounds in ScN2a cells, and that HSP70 and GRP78 levels were not correlated with the antiprion activities of the compounds (Fig. 2F) .
Effects of isoprenoid compounds on cellular cholesterol and protein prenylation
Cholesterol-lowering HMG-CoA reductase inhibitors such as lovastatin reportedly inhibit abnormal PrP formation by perturbing cholesterol synthesis and thereby destabilizing membrane domains (Gilch et al., 2006; Klingenstein et al., 2006; Taraboulos et al., 1995) . Therefore, we examined whether a cholesterol-lowering mechanism is involved in the antiprion action of the isoprenoid compounds. No correlation was found between cellular cholesterol levels and antiprion activities (Fig. 3A) . Neither FOH nor GGOH modified the cellular cholesterol levels of ScN2a cells. Another line of evidence for the cholesterol-independent mechanism of antiprion action was obtained through observation of the lipid raft microdomains of the cell membrane. These lipid raft microdomains are possible sites of PrP conversion or interaction between PrPc and abnormal PrP. Cholera toxin B-binding lipid raft levels of N2a cells and ScN2a cells were not modified by treatment with FOH or GGOH (Fig. 3B) .
Finally, because isoprenoid compounds are also involved in the prenylation of proteins, we examined whether the prenylation of proteins is related to the antiprion activities of isoprenoid compounds or not. We investigated all three types of protein prenylation (Fig. 1D) in ScN2a cells by assaying the unprenylated and prenylated levels of such representative proteins as Ras, Rap1A/B, and Rab7, which are respectively subject to farnesyltransferasemediated prenylation, geranylgeranyltransferase type I-mediated prenylation, and geranylgeranyltransferase type II-mediated prenylation. Results demonstrated that the presence of FOH or GGOH in the medium did not change the proportions of unprenylated protein levels (in the aqueous fractions), and that the prenylated protein levels (in the detergent-rich fractions) of Ras, Rap1A/B, and Rab7 were comparable to those of the control (Fig. 3C) . These results suggest that the prenylation of proteins is not involved in the antiprion activities of isoprenoid compounds in ScN2a cells.
Discussion
This study demonstrated that isoprenoid compounds inhibited abnormal PrP formation in prion-infected cells. Representative compounds JH-III, FOH, and GGOH showed dose-dependent, prion strain-dependent antiprion activity. Structure-activity studies revealed that the most potent antiprion compounds were 15-carbon or 20-carbon isoprenoids with an α-terminal hydroxyl group.
Although many compounds or biological materials have previously been reported to inhibit the abnormal PrP formation in prioninfected cells, isoprenoid compounds have never been reported. They are therefore a new class of antiprion compounds.
The isoprenoid pathway is sited downstream of the mevalonate pathway. Isoprenoids are intermediates in cholesterol biosynthesis. Numerous reports describe that cholesterol modulators have antiprion activity. These compounds reportedly disturb membrane lipid raft microdomains, a possible site of PrP conversion or interaction between PrPc and abnormal PrP (Bate et al., 2004 (Bate et al., , 2010 Gilch et al., 2006 Gilch et al., , 2009 Klingenstein et al., 2006; Kumar et al., 2008; Lewis and Hooper, 2011; Marella et al., 2002; Pani et al., 2007; Prior et al., 2007; Rouvinski et al., 2014; Taraboulos et al., 1995) . In addition, cholesterol metabolism is reportedly impaired in prion-infected cells, and cellular cholesterol levels are connected reciprocally with abnormal PrP levels (Cui et al., 2014) . In the present study, however, two representative antiprion compounds, FOH and GGOH, did not modify cellular cholesterol levels or membrane lipid raft microdomain levels. This result strongly suggests that these isoprenoid compounds exert their antiprion activity in a cholesterol-independent manner.
Results of the present study also suggest that protein prenylation is unlikely to be involved in the mechanism of antiprion action of the isoprenoid compounds. The proportions of either the unprenylated protein levels in the aqueous fractions or the prenylated protein levels in the detergent-rich fractions were not changed by isoprenoid treatment. Prenylation, in which C-terminal cysteine residues are covalently modified with farnesyl or geranylgeranyl isoprenoid groups, is a mechanism through which cytoplasmic proteins associate with the membrane. Protein prenylation is mediated by three protein prenyltransferase enzymes: farnesyltransferase, for farnesylation of proteins such as Ras and nuclear lamins; geranylgeranyltransferase type I, for geranylgeranylation of proteins such as Rho, Rac, and Rap1; and geranylgeranyltransferase type II, for geranylgeranylation of Rab. Among these, prenylated Rab proteins are known to regulate membrane trafficking in vesicle formation, organelle movement, and membrane tethering/fusion. Membrane trafficking along the endocytic-recycling and the endo-lysosomal pathways is reportedly involved in abnormal PrP formation or degradation (Beranger et al., 2002; Borchelt et al., 1992; Caughey and Raymond, 1991; Marijanovic et al., 2009; Taraboulos et al., 1992; Yamasaki et al., 2014) . Therefore, it was natural to infer that isoprenoid supplementation to prion-infected cells would modify protein prenylation levels and thereby cause a reduction in abnormal PrP levels. However, this presumption turned out not to be true because no changes in protein prenylation levels were observed in the present study.
In addition to the non-involvement of cholesterol biosynthesis and protein prenylation, the isoprenoid compounds did not influence any relevant factors such as total cellular and cell surface PrPc levels, autophagosome levels, or heat shock protein levels. At the same time, they were active in a prion strain-dependent manner. Considering all these together, the results suggest that the compounds reduce abnormal PrP levels by directly modifying abnormal PrP formation or turnover. We have experienced similar results in prion-infected cells with amyloidophilic compounds such as compound B, BSB, and styrylbenzoazole derivatives, all of which also showed prion strain-dependent efficacy in vivo (Ishikawa et al., 2004 (Ishikawa et al., , 2006 Kawasaki et al., 2007; Teruya and Doh-ura, 2013) . We have speculated that the prion strain-dependent efficacy of these compounds is attributable to strain-specific structure, biosynthesis, or turnover of abnormal PrP molecules. However, to date, none of these mechanisms of prion strain-dependency has been verified. The present findings of a new class of antiprion compounds might provide clues to elucidate the mechanisms of strain-dependent antiprion activity.
Finally, the findings of this study suggest that the mechanisms of abnormal PrP formation in prion-infected cells are not the same for different prion strains. The findings also suggest that isoprenoid compounds are a new tool for resolving the enigma of prion strain-dependent prion formation. The most excellent isoprenoid compound GGOH in the present study has an EC 50 value comparable to 2-aminothiazole compounds , which are the most effective antiprion compounds reported recently in RML prion-infected N2a cells and animals (Berry et al., 2013; Silber et al., 2013) . This similarity implies that the isoprenoid compound can be anticipated for use as a lead compound and as a source of clues for discovering a new target for remedy development, although the in vivo efficacy of the compound remains to be evaluated.
Materials and methods
Compounds
We obtained all insect-derived substances and their analogues, which include JH-III, methoprene acid, methoprene, corazonin, proctolin, drosocin, cecropin A, α-ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A, adipokinetic hormone G, leucokinin I, leucokinin III, allatotropin, and allatostatin A from commercial sources. Hormones and peptides were dissolved respectively in 100% ethanol and distilled water. The isoprenoid compounds and their related compounds obtained for this study (Sigma-Aldrich) were dissolved in 100% ethanol.
Analysis of PrP and other factors
We used mouse neuroblastoma N2a cells as well as three types of distinct prion strain-infected N2a-derived cells: ScN2a cells infected with the RML prion, N167 cells infected with the 22L prion, and F3 cells infected with the Fukuoka-1 prion. Cells were treated for three days with test materials as described previously (Doh-Ura et al., 2000; Ishikawa et al., 2006; Kawasaki et al., 2007) . Cell lysates were prepared using lysis buffer (0.5% sodium deoxycholate, 0.5% Nonidet P-40, PBS, pH 7.4). The amounts of PrPres, PrPc, β-actin, autophagosomal microtubule-associated protein light chain 3 (LC3), 70-kDa heat shock protein (HSP70), and 78-kDa glucose-regulated protein (GRP78) in the cell lysates were analyzed using immunoblotting with each specific antibody, as described in a previous report (Nishizawa et al., 2014) , or with anti-HSP70 (1:10,000, BD Transduction Labs) or anti-GRP78 (1:5000, BD Transduction Labs). For the analysis of cell-surface PrPc levels in N2a cells and lipid raft microdomain levels in N2a cells and ScN2a cells, flow cytometry was performed using antiPrP monoclonal antibody and fluorescence-conjugated cholera toxin B, respectively, as described in a previous report (Nishizawa et al., 2014) . Cell viability was analyzed (Cell Counting Kit-8; Dojindo Molecular Technologies) to monitor the cytotoxicity of compounds. For each sample, the 50% effective concentration value (EC 50 ) for inhibiting PrPres formation, the 25% cytotoxic concentration value (TC 25 ), and other statistical data were obtained from results of triplicate analyses.
Analysis of cholesterol and protein prenylation
The cholesterol contents of cells were analyzed using a cholesterol assay kit (Amplex Red; Molecular Probes Inc.) according to the manufacturer's instructions. Proportions of cytosolic unprenylated and membrane-bound prenylated proteins were assayed as described previously (Coxon et al., 2005) , using Triton X-114 fractionation to separate the prenylated and unprenylated forms of proteins in whole cell lysates. ScN2a cells treated with farnesol (FOH) or geranylgeraniol (CGOH) for 24 h or 72 h were washed in PBS, then lysed in Triton X-114 buffer (20 mM Tris, 150 mM NaCl, pH 7.5, 1% Triton X-114). Lysates were clarified by centrifugation at 13,000 Â g for 10 min. Then they were incubated at 37°for 10 min. Following centrifugation at 20,000 Â g for 5 min, the aqueous phases (aqueous fractions) were removed to fresh tubes. Buffer without Triton X-114 was added to the detergent-rich phases (detergent-rich fractions) to equalize the volume with the aqueous phases. Then an aliquot of each phase was electrophoresed on a 15% polyacrylamide gel. These were then analyzed by immunoblotting with antibodies against Ras (1:2000, GeneTex), Rap1A/B (1:50, Santa Cruz Biotechnology Inc.), Rab7 (1:1000, Cell Signaling Technology), unprenylated Rap1A (1:100, Santa Cruz Biotechnology Inc.), or β-actin.
